Asepxia Acne Bar Soap
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Acne
Salicylic Acid is an approved or monograph active for acne; this rinse-off bar carries it at 2% — short contact still counts for this active, but a leave-on does more.
A trial-supported active, or a reference standard by mechanism, at a working level; or a first-line active below its studied range.
- Rule
- R2r → Good choice. A first-line active (approved, monograph-listed or named in a current guideline) or a supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level; in a rinse-off product the claim allows; not for a scalp concern.
q1 = first-line | supported · q2 = adequate | plausible · rinse = true · scalp = false
Why this rule exists: Rinse-off exceptions (BPO wash, salicylic acid cleanser) deliver a real but smaller effect than the leave-on form; they cap at 'good choice'. Medicated shampoos for scalp concerns are exempt — the shampoo is the treatment form. Editorial decision 2 Sep 2026, pending advisory review.
Rule R2r decided 413 verdicts across the catalog; “Good choice” is the verdict on 10,340 of 45,446. The full register. - Carrying active
- Salicylic Acid 2%
- 1 · Standing
- First-line — a regulator recognises it for this use; trials support it
Document: § 333.310 Acne active ingredients. (U.S. Food and Drug Administration — 21 CFR Part 333 Subpart D (Topical Acne Drug Products), Code of Federal Regulations via GovInfo), opened July 27, 2026 - 2 · Form
- Adequate — declared at 2%
Studied range: 0.5–2%, from the OTC monograph or label; judge it after about 6 weeks - 3 · Tolerability
- Standard tolerability — fragrance load
Cautions: fragrance. - Evidence dots
- Moderate evidence
Row checked against its sources on July 27, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Guidelines of care for the management of acne vulgaris — Journal of the American Academy of Dermatology (2024), opened July 16, 2026
- 2024 AAD Acne Vulgaris Clinical Guideline Summary — Guideline Central (2024), opened July 16, 2026
- Inside the 2024 AAD Acne Guidelines: New Therapies Join Old Standbys — MDedge (2024), opened July 16, 2026
← Back to the verdict All acne products → Disclose a concentration or correct a fact →
for Excess Oiliness
Rinse-off bar: Salicylic Acid gets seconds of contact, so this supports a routine for excess oiliness rather than treating it.
Nothing here targets the concern directly, but the product’s job — barrier care, gentle cleansing, photoprotection — is the recognised companion to treating it. Rinse-off products carrying leave-on actives land here too.
- Rule
- R6 → Supporting role. A first-line active (approved, monograph-listed or named in a current guideline) or a supported active (trial-backed, or a reference standard by mechanism) or an active with early or mechanistic evidence only or an active researched for the concern and found wanting or an active with no evidence row for the concern yet; in a rinse-off form the claim cannot use.
q1 = first-line | supported | plausible | none | not-assessed · q2 = contact-limited
Why this rule exists: Contact time cannot deliver a leave-on claim; the product is judged on its job (cleansing without aggravating). Explicit exceptions (BPO wash, SA cleanser, medicated shampoos) never reach this rule because their rows set rinse_off_ok.
Rule R6 decided 2,083 verdicts across the catalog; “Supporting role” is the verdict on 7,796 of 45,446. The full register. - Carrying active
- Salicylic Acid 2%
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Contact-limited — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Standard tolerability
- Evidence dots
- Moderate evidence
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- 30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea — Journal of Cosmetic Dermatology — TRUE vehicle (matrix minus SA); investigator-initiated, China Medical University, no declared conflicts (2025), opened July 16, 2026
- Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes — Experimental Dermatology — in vitro SEB-1 sebocytes + rabbit ear; NO human data (2019), opened July 16, 2026
- Clinical Efficacy of a Salicylic Acid-Containing Gel on Acne Management and Skin Barrier Function: A 21-Day Prospective Study — Journal of Cosmetic Dermatology — SINGLE-ARM, not an RCT; L'Oréal/CeraVe-employed co-authors testing their own product; EXCLUDED, see notes (2025), opened July 16, 2026
- 30% supramolecular salicylic acid peels effectively treats acne vulgaris and reduces facial sebum — Journal of Cosmetic Dermatology — self-contrast, no control arm; EXCLUDED (2022), opened July 16, 2026
- Efficacy and safety of a facial serum and a mask containing salicylic acid and lipohydroxy acid in acne management: A randomized controlled trial — Journal of Cosmetic Dermatology — randomized, but BOTH arms received the SA serum (mask vs no mask); no vehicle arm; all authors L'Oréal China; EXCLUDED (2023), opened July 16, 2026
- 2% supramolecular salicylic acid hydrogel vs. adapaline gel in mild to moderate acne vulgaris treatment: A multicenter, randomized, evaluator-blind, parallel-controlled trial. — Journal of Cosmetic Dermatology — n=500, 16 weeks; sebum was MEASURED but the comparator is adapalene, not vehicle, and the abstract reports no sebum result; full text not in PMC. EXCLUDED (no vehicle arm; endpoint result unreported) (2024), opened October 13, 2026
← Back to the verdict All excess oiliness products → Disclose a concentration or correct a fact →
for Blackheads
Salicylic Acid is an approved or monograph active for blackheads; this rinse-off bar carries it at 2% — short contact still counts for this active, but a leave-on does more.
A trial-supported active, or a reference standard by mechanism, at a working level; or a first-line active below its studied range.
- Rule
- R2r → Good choice. A first-line active (approved, monograph-listed or named in a current guideline) or a supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level; in a rinse-off product the claim allows; not for a scalp concern.
q1 = first-line | supported · q2 = adequate | plausible · rinse = true · scalp = false
Why this rule exists: Rinse-off exceptions (BPO wash, salicylic acid cleanser) deliver a real but smaller effect than the leave-on form; they cap at 'good choice'. Medicated shampoos for scalp concerns are exempt — the shampoo is the treatment form. Editorial decision 2 Sep 2026, pending advisory review.
Rule R2r decided 413 verdicts across the catalog; “Good choice” is the verdict on 10,340 of 45,446. The full register. - Carrying active
- Salicylic Acid 2%
- 1 · Standing
- First-line — a regulator recognises it for this use; trials support it
Document: 21 CFR § 333.350 - Labeling of acne drug products. (US Code of Federal Regulations (Legal Information Institute, Cornell Law School)), opened July 27, 2026 - 2 · Form
- Adequate — declared at 2%
Studied range: 0.5–2%, from the OTC monograph or label; judge it after about 6 weeks - 3 · Tolerability
- Standard tolerability
- Evidence dots
- Moderate evidence
Row checked against its sources on July 27, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- OTC monograph, Topical Acne Drug Products — salicylic acid 0.5–2% recognized as an acne treatment active — US Food and Drug Administration
- 2% supramolecular salicylic acid hydrogel vs. adapaline gel in mild to moderate acne vulgaris treatment: A multicenter, randomized, evaluator-blind, parallel-controlled trial — Journal of Cosmetic Dermatology (2024), opened July 17, 2026
← Back to the verdict All blackheads products → Disclose a concentration or correct a fact →
Not judged as a cleanser: surfactant mildness, pH match to skin, rinses clean without stripping cannot yet be measured from the ingredient list (only puts something back can).
- Fragrance
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.